Surette A, Yoo BH, Younis T, Matheson K, et al. Tumor levels of the mediators of ErbB2-driven anoikis resistance correlate with
breast cancer relapse in patients receiving trastuzumab-based therapies. Breast Cancer Res Treat 2021 Mar 16. pii: 10.1007/s10549-021-06164.
PMID: 33728523